Healthcare & Life Sciences

Latham offers life sciences and healthcare industry leaders deep sector knowledge, legal expertise, and commercial and government insight to meet client needs.

Why Latham

Latham’s cross-disciplinary healthcare and life sciences team delivers insightful, practical guidance and sophisticated representation to a full spectrum of companies across the globe, on every type of transaction or dispute a company may face. Many of us hold advanced scientific degrees and have served in senior positions as government regulators, C-Suite executives in leading healthcare and life sciences companies, as well as serving as primary outside counsel for key industry associations.

We regularly navigate commercial and regulatory issues related to the Food and Drug Administration, the Patent Trade and Appeals Board, the European Medicines Agency, the European Commission, and other state, and federal agencies in the US and across Europe.

We deliver:

  • The right team. We work with companies at every stage of development, from fast-growing startups to mature public companies, in virtually every sector and subsector of the industry – including healthcare services, biotechnology, medtech and medical devices. With an outstanding global platform, we can scale our client teams to meet client needs — whether that means drawing on best-of-the-best capabilities in public company representation, M&A, capital markets, regulatory advice or IP and securities litigation.
  • Insight. Our broad client base and on-the-ground presence in the world’s healthcare and life sciences hubs afford us an expansive view of the commercial, scientific, regulatory, and political trends shaping the markets in which clients operate. We know how traditional regulatory regimes work, and quickly set the bar for successful strategies in dynamic and uncertain regulatory landscapes.
  • Results. By leveraging decades of experience and a culture of innovation, we have developed an impressive track record navigating many of the industry’s largest, most complex, and most consequential deals through commercial and regulatory issues, as well as winning precedent-setting litigation and trials.


Our Experience

Awards & Rankings

  • Capital Markets Partner Named Healthcare | Life Sciences Trailblazer - February 28, 2021
  • Jeff Bjork Named to Turnarounds & Workouts’ 2020 Outstanding Restructuring Lawyers List - January 07, 2021
  • Latham Litigators Among Most Honored in 2020 - December 30, 2020
  • Boston Office Managing Partner Named Go To Business Lawyer - December 30, 2020
  • Latham Named Capital Markets Group of the Year - December 13, 2020

A best-in-market corporate team with a sterling reputation for its counsel on M&A transactions, public and private securities offerings, and strategic partnerships. Acts for early-stage and long-established companies as well as banks and financiers. Contentious practice with expertise in handling everything from white-collar investigations to intellectual property disputes. 

Chambers 2020 USA


Sachs Associates 14th Annual European Life Sciences CEO ForumWebcast – A Look Ahead at the Biden Administration’s Regulatory and Enforcement PrioritiesWebcast – FDA Regulatory Updates and 2020 Outlook for Vaping and Cannabis-Derived Substances

Media Coverage

Healthcare & Life Sciences Trailblazer: Nathan AjiashviliAstellas Wins Sole Ownership of Stem-Cell Production PatentsLaw Firm of the Week: Latham & Watkins


Firm Advises Boston Scientific in US$1.07 Billion Acquisition of Lumenis LTD. Surgical Business Latham Adds Another Skilled Patent Litigator to Leading IP Litigation PracticeCapital Markets Partner Named Healthcare | Life Sciences Trailblazer

Thought Leadership

EU-UK Trade and Cooperation Agreement: Life Sciences CompaniesLife Sciences Law Review - 9th Edition, France ChapterAntitrust Enforcement in Health Care: A Risky and Evolving Landscape

Webcasts & Podcasts

Podcast – Healthcare Tech: How Are Licensing Agreements Bridging the Industry Divide?Podcast – Healthcare Tech: How Will the FDA Regulatory Framework Adapt to AI?A Look Ahead at the Biden Administration’s Regulatory and Enforcement Priorities